Skip to main content
SpringerLink
Log in

Managing Cutaneous Manifestations of Hyperandrogenic Disorders

The Role of Oral Contraceptives

  • Therapy in Practice
  • Published:
Treatments in Endocrinology

Abstract

Cutaneous manifestations of hyperandrogenic disorders (acne, seborrhea, hirsutism and androgenetic alopecia) can be caused by elevated levels of free testosterone or androgen precursors. In women with normal serum levels of testosterone or androgen precursors, enhanced local conversion to testosterone, or to the more potent androgen dihydrotestosterone, may lead to increased androgen activity in the pilosebaceous unit. Large individual variations in the response to normal or elevated androgens suggests considerable differences in local androgen metabolism and androgen receptor-mediated activities, which may partly be related to genetic disposition. Androgens cause opposite effects on hair follicles in the scalp compared with the face and body, and there are large differences in the length of anagen phase. Androgens enhance sebum production and keratinization, prolong the growth phase of face and body hair, stimulate the transformation of vellus to terminal hair, and shorten the anagen phase of scalp hair. Estrogens may antagonize the androgen-induced actions on sebaceous glands and hair follicles.

Treatment with oral contraceptives (OCs) reduces the production of androgens and androgen precursors and increases sex hormone-binding globulin, resulting in a decrease of free testosterone levels. According to type and dose, the estrogen and progestogen components of OCs may directly reduce the effect of androgens within sebaceous glands and hair follicles. Therefore, OCs with a predominant estrogen effect may improve mild to moderate forms of acne and seborrhea, hirsutism and androgenetic alopecia, in a time-dependent manner.

In women who do not respond satisfactorily, treatment with OCs containing a progestogen with antiandrogenic activity is recommended. In many women with severe acne or hirsutism, a considerable increase in the local concentration of the antiandrogenic progestogen is required to reduce the androgenic interaction with the androgen receptor. For this therapy, an OC containing cyproterone acetate can be used. If necessary, the dose of cyproterone acetate can be increased in a stepwise manner. While androgenetic alopecia is best treated with a low-dose OC containing cyproterone acetate (optimal effect occurs after at least 12 months of therapy), severe acne and hirsutism are significantly improved after 6–12 months of regimens containing high doses of cyproterone acetate (25–100 mg/day). After termination of treatment the disorders may reappear, therefore treatment with suitable low-dose formulations is recommended to maintain the therapeutic effect.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Table I
Table II
Table III
Table IV

Similar content being viewed by others

References

  1. Randall VA. Androgens and human hair growth. Clin Endocrinol 1994; 40: 439–57

    Article  CAS  Google Scholar 

  2. Azziz R, Carmina E, Sawaya ME. Idiopathic hirsutism. Endocr Rev 2000; 21: 347–62

    Article  PubMed  CAS  Google Scholar 

  3. Deplewski D, Rosenfield RL. Role of hormones in pilosebaceous unit development. Endocr Rev 2000; 21: 363–92

    Article  PubMed  CAS  Google Scholar 

  4. Bergfeld WF. Androgenetic alopecia: an autosomal dominant disorder. Am J Med 1995; 98 Suppl. 1A: 95S–8S

    Article  PubMed  CAS  Google Scholar 

  5. Serafini P, Lobo RA. Increased 5α-reductase activity in idiopathic hirsutism. Fertil Steril 1985; 43: 74–8

    PubMed  CAS  Google Scholar 

  6. Jenkins JS, Ash S. The metabolism of testosterone by human skin in disorders of hair growth.J Endocrinol 1973; 59: 345–51

    Article  PubMed  CAS  Google Scholar 

  7. Cassidenti DL, Paulson RJ, Serafini P, et al. Effects of sex steroids on skin 5α-redictase activity in vitro. Obstet Gynecol 1991; 78: 102–7

    Google Scholar 

  8. Voigt W, Hsia SL. Further studies on testosterone 5α-reductase of human skin. J Biol Chem 1973; 248: 4280–5

    PubMed  CAS  Google Scholar 

  9. Rabe T, Kowald A, Ortmann J, et al. Inhibition of skin 5 alpha-reductase by oral contraceptive progestins in vitro. Gynecol Endocrinol 2000; 14: 223–30

    Article  PubMed  CAS  Google Scholar 

  10. Giacomini M, Wright F. The effects of progesterone and pregnanedione on the reductive metabolism of dihydrotestosterone in human skin. J Steroid Biochem Molec Biol 1980; 13:645–51

    CAS  Google Scholar 

  11. Thiboutot D, Harris G, Iles V, et al. Activity of the type I 5-reductase exhibits regional differences in isolated sebaceous glands and whole skin. J Invest Dermatol 1995; 105: 209–14

    Article  PubMed  CAS  Google Scholar 

  12. Guy R, Ridden C, Kealey T. The improved organ maintenance of the human sebaceous gland: modeling in vitro the effects of epidermal growth factor, androgens, estrogens, 13-cis retinoic acid, and phenol red. J Invest Dermatol 1996 Mar; 106(3): 454–60

    Article  PubMed  CAS  Google Scholar 

  13. Castello R, Tosi F, Perrone F, et al. Outcome of long-term treatment with the 5α-reductase inhibitor finasteride in idiopathic hirsutism: clinical and hormonal effects during a 1-year course of therapy and 1-year follow-up. Fertil Steril 1996; 66: 734–40

    PubMed  CAS  Google Scholar 

  14. Moltz L, Haase F, Schwartz U, Hammerstein J. Treatment of virilized women with intramuscular administration of cyproterone acetate [in German]. Geburtshilfe Frauenheilkd 1983 May; 43(5): 281–7

    Article  PubMed  CAS  Google Scholar 

  15. vanWayjen RGA, van denEnde A. Experience in the long-term treatment of patients with hirsutism and/or acne with cyproterone acetate-containing preparations: efficacy, metabolic and endocrine effects. Exp Clin Endocrinol 1995; 103: 241–51

    Article  Google Scholar 

  16. Marcondes JAM, Wajchenberg BL, Abujamra AC, et al. Monthly cyproterone acetate in the treatment of hirsute women: clinical and laboratory effects. Fertil Steril 1990; 53: 40–4

    PubMed  CAS  Google Scholar 

  17. Sawaya ME, Price VH. Different levels of 5α-reductase type I and II, aromatase, and androgen receptor in hair follicles of women and men with anrogenetic alopecia. J Invest Dermatol 1997; 109: 296–300

    Article  PubMed  CAS  Google Scholar 

  18. Rittmaster RS. Medical treatment of androgen-dependent hirsutism. J Clin Endocrinol Metab 1995; 80: 2559–63

    Article  PubMed  CAS  Google Scholar 

  19. Bergfeld WF. Hirsutism in women. Postgrad Med 2000; 107: 93–104

    Article  PubMed  CAS  Google Scholar 

  20. Rittmaster RS. Androgen conjugates: physiology and clinical significance. Endocr Rev 1993; 14: 121–32

    PubMed  CAS  Google Scholar 

  21. Gompel A, Wright F, Kuttenn F, et al. Contribution of plasma androstenedione to 5α-androstanediol glucuronide in women with idiopathic hirsutism. J Clin Endocrinol Metab 1986; 62: 441–4

    Article  PubMed  CAS  Google Scholar 

  22. Gruschke A, Kuhl H. Validity of radioimmunological methods for determining free testosterone in serum. Fertil Steril 2001; 76: 576–82

    Article  PubMed  CAS  Google Scholar 

  23. Barbieri RL. Hyperandrogenism. In: Wallach EE, Zacur HA, editors. Reproductive medicine and surgery. St Louis (MO): Mosby, 1995: 209–29

    Google Scholar 

  24. Kelly CJG, Gordon D. The effect of metformin on hirsutism in polycystic ovary syndrome. Eur J Endocrinol 2002; 147: 217–21

    Article  PubMed  CAS  Google Scholar 

  25. Wiegratz I, Jung-Hoffmann C, Kuhl H. Effect of two oral contraceptives containing ethinylestradiol and gestodene or norgestimate upon androgen parameters and serum binding proteins. Contraception 1995; 51: 341–6

    Article  PubMed  CAS  Google Scholar 

  26. Jung-Hoffmann C, Heidt F, Kuhl H. Effect of two oral contraceptives containing 30 μg ethinylestradiol and 75 μg gestodene or 150 μg desogestrel upon various hormonal parameters. Contraception 1988; 38: 593–603

    Article  PubMed  CAS  Google Scholar 

  27. Kuhl H, Gahn G, Romberg G, et al. A randomized cross-over comparison of two low dose oral contraceptives upon hormonal and metabolic parameters: I. effects upon sexual hormone levels. Contraception 1985; 31: 583–93

    Article  PubMed  CAS  Google Scholar 

  28. New MI. Steroid 21-hydroxylase deficiency (congenital adrenal hyperplasia).Am J Med 1885; 98 Suppl 1A: 2S–8S

    Google Scholar 

  29. Moran C, Downing Potter H, Reyna R, et al. Prevalence of 3ß-hydroxysteroid dehydrogenase-deficient nonclassic adrenal hyperplasia in hyperandrogenic women with adrenal androgen excess. Am J Obstet Gynecol 1999; 181: 596–600

    Article  PubMed  CAS  Google Scholar 

  30. Oettel M, Elger W, Ernst M, et al. Experimentelle Endokrinpharmakologie. In: Teichmann AT, editor. Dienogest —Präklinik und Klinik eines Oestagens. Berlin: de Gruyter, 1995: 11–21

    Google Scholar 

  31. Muhn P, Krattenmacher R, Beier S, et al. Drospirenone: a novel progestogen with antimineralocorticoid and antiandrogenic activity: pharmacological characterization in animal models. Contraception 1995 Feb; 51(2): 99–110

    Article  PubMed  CAS  Google Scholar 

  32. Jasonni VM, Bulletti C, Naldi S, et al. Treatment of hirsutism by an association of oral cyproterone acetate and transdermal 17ß-estradiol. Fertil Steril 1991; 55: 742–5

    PubMed  CAS  Google Scholar 

  33. Fern M, Rose DP, Fern EB. Effect of oral contraceptives on plasma androgenic steroids and their precursors. Obstet Gynecol 1978; 51: 541–4

    Article  PubMed  CAS  Google Scholar 

  34. Palatsi R, Hirvensalo E, Liukko P, et al. Serum total and unbound testosterone and sex hormone binding globulin (SHBG) in female acne patients treated with two different oral contraceptives. Acta Derm Venereol 1984; 64: 517–23

    PubMed  CAS  Google Scholar 

  35. Kaiser E. Wirkung eines neuen hormonalen Kontrazeptivums (Neo-Eunomin) bei Frauen mit Androgenisierungserscheinungen. Geburtsh Frauenheilk 1984; 44: 651–5

    Article  PubMed  CAS  Google Scholar 

  36. Carlborg L. Cyproterone acetate versus levonorgestrel combined with ethinyl estradiol in the treatment of acne. Acta Obstet Gynecol Scand Suppl 1986; 134: 29–32

    Article  PubMed  CAS  Google Scholar 

  37. Worret I, Arp W, Zahradnik HP, et al. Acne resolution rates: results of a single-blind, randomized, controlled, parallel phase III trial with EE/CMA (Belara) and EE/LNG (Microgynon). Dermatology 2001; 203: 38–44

    Article  PubMed  CAS  Google Scholar 

  38. Lemay A, Dewailly SD, Grenier R, et al. Attenuation of mild hyperandrogenic activity in postpuberal acne by a triphasic oral contraceptive containing low doses of ethynyl estradiol and d,l-norgestrel. J Clin Endocrinol Metab 1990; 71: 8–14

    Article  PubMed  CAS  Google Scholar 

  39. Jung-Hoffmann C, Kuhl H. Divergent effects of two low-dose oral contraceptives on sex hormone-binding globulin and free testosterone. Am J Obstet Gynecol 1987; 156: 199–203

    PubMed  CAS  Google Scholar 

  40. Refn H, Kjaer A, Lebech AM, et al. Clinical and hormonal effects of two oral contraceptives: correlations to serum concentrations of levonorgestrel and gestodene. Contraception 1990; 41: 259–68

    Article  PubMed  CAS  Google Scholar 

  41. van der Vange N, Blankenstein MA, Kloosterboer HJ, et al. Effects of seven low-dose combined oral contraceptives on sex hormone binding globulin, cortico-steroid binding globulin, total and free testosterone. Contraception 1990; 41: 345–51

    Article  PubMed  Google Scholar 

  42. Coenen CMH, Thomas CMG, Borm GF, et al. Changes in androgens during treatment with four low-dose contraceptives. Contraception 1996; 53: 171–6

    Article  PubMed  CAS  Google Scholar 

  43. Gaspard UJ, Romus MA, Gillain D, et al. Plasma hormone levels in women receiving new oral contraceptives containing ethinylestradiol plus levonorgestrel and desogestrel. Contraception 1983; 27: 577–90

    Article  PubMed  CAS  Google Scholar 

  44. Gaspard UJ, Dubois M, Gillain D, et al. Ovarian function is effectively inhibited by a low-dose triphasic oral contraceptive containing ethinylestradiol and levonorgestrel. Contraception 1984; 29: 305–18

    Article  PubMed  CAS  Google Scholar 

  45. Kuhnz W, Baumann A, Staks T, et al. Pharmacokinetics of gestodene and ethinylestradiol in 14 women in three months of treatment with a new tri-step combination oral contraceptive: serum protein binding of gestodene and influence of treatment on free and total testosterone levels in the serum. Contraception 1993; 48: 303–22

    Article  PubMed  CAS  Google Scholar 

  46. Lucky AW, Henderson TA, Olson WH, et al. Effectiveness of norgestimate and ethinylestradiol in treating moderate acne vulgaris. J Am Acad Dermatol 1997; 37: 746–54

    Article  PubMed  CAS  Google Scholar 

  47. Redmond GP, Olson WH, Lippman JS, et al. Norgestimate and ethinyl estradiol in the treatment of acne vulgaris: a randomized, placebo-controlled trial. Obstet Gynecol 1997; 89: 615–22

    Article  PubMed  CAS  Google Scholar 

  48. Thiboutot D, Archer DF, Lemay A, et al. A randomized, controlled trial of a low-dose contraceptive contaning 20 μg of ethinyl estradiol and 100 μg of levonorgestrel for acne treatment. Fertil Steril 2001; 76: 461–8

    Article  PubMed  CAS  Google Scholar 

  49. Thorneycroft ICH, Stanczyk FZ, Bradshaw KD, et al. Effect of low-dose oral contraceptives on androgenic markers and acne. Contraception 1999; 60:255–62

    Article  PubMed  CAS  Google Scholar 

  50. Dieben TOM, Vromans L, Theeuwes A, et al. The effects of CTR-24, a biphasic oral contraceptive combination, compared to Diane-35 in women with acne. Contraception 1994; 50: 373–82

    Article  PubMed  CAS  Google Scholar 

  51. Mango D, Ricci S, Manna P, et al. Clinical and hormonal effects of ethinylestradiol combined with gestodene and desogestrel in young women with acne vulgaris. Contraception 1996; 53: 163–70

    Article  PubMed  CAS  Google Scholar 

  52. Luderschmidt C, Schreiber G, Moltz L. The significance of antiandrogenic properties of oral contraceptives in androgen influenced skin disorders: a double blind study using two different OCs containing 30 μg EE and 2mg dienogest and 35 μg EE and 2mg cyproterone acetate. In: Kuhl H, Nikolov R, editors. Re-evaluation of contraceptive steroids. Bad Blankenburg: Harfe Verlag, 1998: 37–43

    Google Scholar 

  53. Zahradnik HP, Goldberg J, Andreas JO. Efficacy and safety of the new antiandrogenic oral contraceptive Belara. Contraception 1998; 57: 103–9

    Article  PubMed  CAS  Google Scholar 

  54. Falsetti L, Gambera A, Tisi G. Efficacy of the combination ethinyl oestradiol and cyproterone acetate on endocrine, clinical and ultrasonographic profile in polycystic ovarian syndrome. Hum Reprod2001; 16: 36–42

    Article  PubMed  CAS  Google Scholar 

  55. Venturoli S, Marescalchi O, Colombo FM, et al. A prospective randomized trial comparing low dose flutamide, finasteride, ketoconazole, and cyproterone acetate-estrogen regimens in the treatment of hirsutism. J Clin Endocrinol Metab 1999; 84: 1304–10

    Article  PubMed  CAS  Google Scholar 

  56. Fruzzetti F, Bersi C, Parrini D, et al. Treatment of hirsutism: comparisons between different antiandrogens with central and peripheral effects. Fertil Steril 1999; 71: 445–51

    Article  PubMed  CAS  Google Scholar 

  57. Barth JH, Cherry CA, Wojnarowska F, et al. Cyproterone acetate for severe hirsutism: results of a double-blind dose-ranging study. Clin Endocrinol 1991; 35: 5–10

    Article  CAS  Google Scholar 

  58. O’Brien RC, Cooper ME, Murray RML, et al. Comparison of sequential cypoterone acetate/estrogen vs Spironolactone / oral contraceptive in the treatment of hirsutism. J Clin Endocrinol Metab 1991; 72: 1008–13

    Article  PubMed  Google Scholar 

  59. Erenus M, Yücelten D, Gürbüz O, et al. Comparison of spironolactone-oral contraceptive vs Cyproterone acetate-estrogen regimens in the treatment of hirsutism. Fertil Steril 1996; 66: 216–9

    PubMed  CAS  Google Scholar 

  60. Hammerstein J, Meckies J, Leo-Rossberg I, et al. Use of cyproterone acetate (CPA) in the treatment of acne, hirsutism and virilism. J Steroid Biochem 1975 Jun; 6(6): 827–36

    Article  PubMed  CAS  Google Scholar 

  61. Moltz L, Schwartz U, Hamerstein J. Die klinische Andwendung von Anti-androgenen bei der Frau. Gynäkologe 1980; 13: 1–17

    PubMed  CAS  Google Scholar 

  62. Moltz L. Differenzierter Einsatz von Cyproteronacetat bei verschiedenen androgenbedingten Krankheitsbildern der Frau. In: Breckwoldt M, editor. Diagnostik und Therapie von Androgenisierungserscheinungen bei der Frau. Berlin: Diesbach Verlag, 1992: 154–161

    Google Scholar 

  63. Carmina E, Lobo RA. A comparison of the relative efficacy of antiandrogens for the treatment of acne in hyperandrogenic women. Clin Endocrinol 2002; 57: 231–4

    Article  CAS  Google Scholar 

  64. Hammerstein J, Moltz L, Schwartz U. Antiandrogens in the treatment of acne and hirsutism. J Steroid Biochem 1983; 19: 591–7

    Article  PubMed  CAS  Google Scholar 

  65. Holdaway IM, Croxson MS, Evans MC, et al. Effect of cyproterone acetate on glucocorticoid secretion in patients treated for hirsutism. Acta Endocrinol (Copenh) 1983; 104: 222–6

    CAS  Google Scholar 

  66. Schützel H, Neumann F. Potential risk of intrauterine feminization in man from the antiandrogen cyproterone acetate (CPA) in recommended dose regimens [abstract]. XII World Congress on Gynecology and Obstetrics; 1988 Oct; Rio de Janeiro. 703

  67. Kokaly W, McKenna TJ. Relapse of hirsutism following long-term successful treatment with oestrogen-progestogen combination. Clin Endocrinol 2000; 52: 379–82

    Article  CAS  Google Scholar 

  68. Porcile A, Gallardo E. Oral contraceptives containing desogestrel in the maintenance of the remission of hirsutism: monthly versus bimonthly treatment. Contraception 1991; 44: 533–40

    Article  PubMed  CAS  Google Scholar 

  69. Ibanez L, Potau N, Marcos MV, et al. Treatment of hirsutism, hyperandrogenism, oligomenorrhea, dyslipidemia, and hyperinsulinism in nonobese, adolescent girls: effect of flutamide. J Clin Endocrinol Metab 2000; 85: 3251–5

    Article  PubMed  CAS  Google Scholar 

  70. Venturoli S, Paradisi R, Bagnoli A, et al. Low-dose flutamide (125 mg/day) as maintenance therapy in the treatment of hirsutism. Horm Res 2001; 56: 25–31

    Article  PubMed  CAS  Google Scholar 

  71. Erenus M, Yücelten D, Durmusoglu F, et al. Comparison of finasteride versus spironolactone in the treatment of idiopathic hirsutism. Fertil Steril 1997; 68: 1000–3

    Article  PubMed  CAS  Google Scholar 

  72. Müderris II, Bayram F, Güven M. A prospective, randomized trial comparing flutamide (250 mg/d) and finasteride (5 mg/d) in the treatment of hirsutism. Fertil Steril 2000; 73: 984–7

    Article  PubMed  Google Scholar 

  73. Sahin Y, Dilber S, Kelestimur F. Comparison of Diane 35 and Diane 35 plus finasteride in the treatment of hirsutism. Fertil Steril 2001; 75: 496–500

    Article  PubMed  CAS  Google Scholar 

  74. Castelo-Branco C, Martinez de Osaba MJ, Pons F, et al. Gonadotropin-releasing hormone analog plus an oral contraceptive containing desogestrel in women with severe hirsutism: effects on hair, bone, and hormone profile after 1-year use. Metabolism 1997; 46: 437–40

    Article  PubMed  CAS  Google Scholar 

Download references

Acknowledgements

No sources of funding were used to assist in the preparation of this manuscript. The authors have no conflicts of interest that are directly relevant to the content of this manuscript.

Author information

Authors and Affiliations

  1. Department of Obstetrics and Gynecology, J. W. Goethe University Frankfurt, Theordor-Stern-Kai 7, D-60590, Frankfurt am Main, Germany

    Inka Wiegratz &  Herbert Kuhl

Authors
  1. Inka Wiegratz
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Herbert Kuhl
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Herbert Kuhl.

Rights and permissions

Reprints and permissions

About this article

Cite this article

Wiegratz, I., Kuhl, H. Managing Cutaneous Manifestations of Hyperandrogenic Disorders. Treat Endocrinol 1, 373–386 (2002). https://doi.org/10.2165/00024677-200201060-00003

Download citation

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.2165/00024677-200201060-00003

Keywords

Search

Navigation